Novo Nordisk Falls More Than 8% Premarket After Ziltivekimab Shows No Significant MACE-Risk Reduction vs. Placebo
Novo Nordisk shares fell more than 8% in premarket trading after the company said its anti-inflammatory drug Ziltivekimab showed no significant difference from placebo in reducing the risk of major adverse cardiovascular events, or MACE.
Novo Nordisk shares fell more than 8% in premarket trading after the company said its anti-inflammatory drug Ziltivekimab showed no significant difference from placebo in reducing the risk of major adverse cardiovascular events, or MACE.